ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy.

IF 3.4 2区医学 Q2 ONCOLOGY

Annals of Surgical Oncology Pub Date : 2025-08-01 Epub Date: 2025-05-21 DOI:10.1245/s10434-025-17458-8

Kojiro Omiya, Atsushi Oba, Kota Sugiura, Aya Maekawa, Takafumi Mie, Kosuke Kobayashi, Yoshihiro Ono, Hiromichi Ito, Yosuke Inoue, Yu Takahashi

引用次数: 0

查看原文本刊更多论文

ASO作者反思：优化可切除胰腺癌的治疗：ca19 - 9bb0 500 U/mL作为新辅助治疗的生物学指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Surgical Oncology 医学-外科

CiteScore

5.90

自引率

10.80%

发文量

1698

审稿时长

2.8 months

期刊介绍： The Annals of Surgical Oncology is the official journal of The Society of Surgical Oncology and is published for the Society by Springer. The Annals publishes original and educational manuscripts about oncology for surgeons from all specialities in academic and community settings.